Favorable ICH reversal outcomes linked to shorter door-to-treatment time

For individuals with anti-coagulation-associated intracerebral hemorrhage, a door-to-treatment time of 60 minutes or fewer was associated with decreased mortality and discharge to hospice care, according to research from JAMA Neurology.
“Prior clinical trials of coagulopathy reversal have demonstrated a reduction in [intracerebral hemorrhage] expansion and improved clinical outcome,” Kevin N. Sheth, MD, professor of neurology and neurosurgery at the Yale Center for Brain and Mind Health, Yale University School of Medicine, and colleagues wrote. “However, there was not

For individuals with anti-coagulation-associated intracerebral hemorrhage, a door-to-treatment time of 60 minutes or fewer was associated with decreased mortality and discharge to hospice care, according to research from JAMA Neurology.
“Prior clinical trials of coagulopathy reversal have demonstrated a reduction in [intracerebral hemorrhage] expansion and improved clinical outcome,” Kevin N. Sheth, MD, professor of neurology and neurosurgery at the Yale Center for Brain and Mind Health, Yale University School of Medicine, and colleagues wrote. “However, there was not